Compagnie Lombard Odier SCmA’s Enlivex Therapeutics ENLV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Hold |
0
| – | – | – | 543 |
|
|
2023
Q4 | – | Sell |
-65,000
| Closed | -$104K | – | 592 |
|
|
2023
Q3 | $104K | Hold |
65,000
| – | – | ﹤0.01% | 348 |
|
|
2023
Q2 | $171K | Hold |
65,000
| – | – | ﹤0.01% | 292 |
|
|
2023
Q1 | $225K | Buy |
65,000
+15,000
| +30% | +$52K | 0.01% | 272 |
|
|
2022
Q4 | $190K | Hold |
50,000
| – | – | 0.01% | 300 |
|
|
2022
Q3 | $211K | Hold |
50,000
| – | – | 0.01% | 291 |
|
|
2022
Q2 | $223K | Hold |
50,000
| – | – | 0.01% | 278 |
|
|
2022
Q1 | $279K | Buy |
50,000
+7,000
| +16% | +$39.1K | 0.01% | 271 |
|
|
2021
Q4 | $247K | Buy |
43,000
+8,000
| +23% | +$46K | ﹤0.01% | 332 |
|
|
2021
Q3 | $353K | Buy |
35,000
+10,000
| +40% | +$101K | 0.01% | 288 |
|
|
2021
Q2 | $220K | Hold |
25,000
| – | – | ﹤0.01% | 331 |
|
|
2021
Q1 | $267K | Buy |
+25,000
| New | +$267K | 0.01% | 350 |
|